Černá Hora - chorvatština - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

društvo za trgovinu, promet i usluge "farmegra" d.o.o. podgorica - drospirenon, estradiol - film tableta - 2 mg + 1 mg

Černá Hora - chorvatština - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

"evropa lek pharma" doo podgorica - norgestrel, estradiol - obložena tableta - 0.5mg + 2mg; 2mg

Evropská unie - chorvatština - EMA (European Medicines Agency)

sanofi-aventis deutschland gmbh - insulin human - Šećerna bolest - lijekovi koji se koriste u dijabetesu - diabetes mellitus gdje je potrebno liječenje inzulinom. inzulin ljudske winthrop rapid je pogodan za liječenje hiperglikemijsku komu i ketoacidoza, kao i za postizanje unaprijed, intra - i postoperativna stabilizacija u bolesnika sa šećernom bolešću.

Evropská unie - chorvatština - EMA (European Medicines Agency)

roche registration gmbh - atezolizumab - carcinoma, transitional cell; carcinoma, non-small-cell lung; urologic neoplasms; breast neoplasms; small cell lung carcinoma - antineoplastična sredstva - urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or - who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancer tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies (see section 5. tecentriq, in combination with nab paclitaxel and carboplatin, is indicated for the first line treatment of adult patients with metastatic non-squamous nsclc who do not have egfr mutant or alk positive nsclc (see section 5. tecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. small cell lung cancertecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of adult patients with extensive-stage small cell lung cancer (es-sclc) (see section 5. hepatocellular carcinomatecentriq, in combination with bevacizumab, is indicated for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (hcc) who have not received prior systemic therapy (see section 5. urothelial carcinomatecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma (uc):- after prior platinum containing chemotherapy, or- who are considered cisplatin ineligible, and whose tumours have a pd-l1 expression ≥ 5% (see section 5. non-small cell lung cancertecentriq as monotherapy is indicated for the first-line treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumours have a pd-l1 expression ≥ 50% tumour cells (tc) or ≥ 10% tumour-infiltrating immune cells (ic) and who do not have egfr mutant or alk-positive nsclc (see section 5. tecentriq u monoterapiji namijenjen za liječenje odraslih bolesnika s lokalno-uobičajena ili metastatskih НМРЛ nakon što je ranije kemoterapije. patients with egfr mutant or alk positive nsclc should also have received targeted therapies before receiving tecentriq (see section 5. triple-negative breast cancertecentriq in combination with nab-paclitaxel is indicated for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (tnbc) whose tumours have pd-l1 expression ≥ 1% and who have not received prior chemotherapy for metastatic disease.

Evropská unie - chorvatština - EMA (European Medicines Agency)

steba biotech s.a - padeliporfin di-kalija - prostatske neoplazme - antineoplastična sredstva - tookad prikazan kao monoterapija za liječenje odraslih bolesnika s prethodno liječenih liječenje, jednostrano, nizak rizik, аденокарцинома prostate s očekivanom trajanju života ≥ 10 godina:klinička faza Т1с ili t2a;na skali Глисона ≤ 6, na temelju visoke rezolucije biopsije strategije;psa ≤ 10 ng/ml;3 pozitivan rak jezgre s najvećom raka jezgre dužine 5 mm u bilo kojem jednoj jezgri ili 1-2 pozitivnom raku jezgre s ≥ 50 % raka implikacija na bilo koji jedan kernel ili gustoća psa ≥ 0. 15 ng/ml/cm3.

Chorvatsko - chorvatština - HALMED (Agencija za lijekove i medicinske proizvode)

gedeon richter plc., gyömrői út 19-21, budimpešta, mađarska - dezogestrel - filmom obložena tableta - 0,075 mg - urbroj: jedna filmom obložena tableta sadrži 0,075 mg dezogestrela

Chorvatsko - chorvatština - HALMED (Agencija za lijekove i medicinske proizvode)

gedeon richter plc., gyömrői út 19-21, budimpešta, mađarska - estradiol hemihidrat - transdermalni sprej, otopina - 1,53 mg po potisku - urbroj: jedan potisak sadrži 1,53 mg estradiola (što odgovara 1,58 mg estradiol hemihidrata)

Chorvatsko - chorvatština - HALMED (Agencija za lijekove i medicinske proizvode)

gedeon richter plc., gyömrői út 19-21, budimpešta, mađarska - dienogestum, ethinylestradiolum - filmom obložena tableta - 2 mg+0,03 mg - urbroj: jedna filmom obložena tableta sadrži 2 mg dienogesta i 0,03 mg etinilestradiola

Chorvatsko - chorvatština - HALMED (Agencija za lijekove i medicinske proizvode)

novo nordisk a/s, novo alle, bagsvaerd, danska - estradiol hemihidrat noretisteronacetat - filmom obložena tableta - 1 mg + 1 mg - urbroj: jedna crvena filmom obložena tableta sadrži 1 mg estradiola (u obliku estradiol hemihidrata) jedna bijela filmom obložena tableta sadrži 1 mg estradiola (u obliku estradiol hemihidrata) i 1 mg noretisteronacetata

Chorvatsko - chorvatština - HALMED (Agencija za lijekove i medicinske proizvode)

pfizer croatia d.o.o., slavonska avenija 6, zagreb, hrvatska - medroksiprogesteronacetat - tableta - 10 mg - urbroj: jedna tableta sadrži 10 mg medroksiprogesteronacetata